Velarion · Company Intelligence
Compensation Brief
Fiscal year 2023 · Filings through 2026-04-30

Chimerix (CMRX)

CEO Mike Andriole was paid $1,312,421 in fiscal year 2023, ↓ down 21.5% from fiscal year 2022, the 1st percentile of its disclosed peer group (SEC filing 0001117480-24-000010 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$1,517,854
Mike Sherman total, FY2023
Former President and Chief Executive Officer — highest-paid officer; CEO Mike Andriole: $1,312,421
1st
CEO (Mike Andriole) pay percentile vs peers
—
CEO-to-median pay ratio
82.99%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

01

Summary Compensation Table — fiscal year 2023

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Mike Sherman$514,695$0$183,112$778,511$0$0$41,536$1,517,854
Former President and Chief Executive Officer
Mike Andriole528,473093,135399,282280,500011,0311,312,421
President and Chief Executive Officer
Allen Melemed488,408050,708215,588166,059011,031931,794
Chief Medical Officer
Michael Alrutz432,180042,257179,656128,574011,187793,854
Senior Vice President, General Counsel and Corporate Secretary

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2023 totalFY2022 totalFY2021 totalΔ FY2022→2023
Mike Sherman$1,517,854$4,061,403—↓ −2,543,549
Mike Andriole1,312,4211,672,620—↓ −360,199
Allen Melemed931,7941,472,116—↓ −540,322
Michael Alrutz793,854———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Chimerix's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CMRX reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against CMRX
5 companies name CMRX as a compensation peer

The list of companies that name CMRX as a peer is temporarily unavailable — recheck shortly.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2023 total
Catherine L. GillissFormer director (through FY2023)$104,522
Fred A. MiddletonIndependent Director$119,522
Lisa L. DeckerIndependent Director$67,778
Marc D. KozinIndependent Director—
Martha J. DemskiLead Independent Director$144,522
Patrick MachadoIndependent Director$124,522
Pratik S. MultaniIndependent Director$104,522
Robert J. MeyerIndependent Director$117,022
Vicki VakienerIndependent Director$107,022
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Mike AndrioleDirector2025-01-07A900,000$0$0Derivative, Class A CommonForm 4 ↗
Mike AndrioleDirector2025-01-07A150,00000RSUForm 4 ↗
Michael AlrutzSVP AND GENERAL COUNSEL2025-01-07A250,00000Derivative, Class A CommonForm 4 ↗
Michael AlrutzSVP AND GENERAL COUNSEL2025-01-07A41,66700RSUForm 4 ↗
Thomas J. RigaCOO and CCO2025-01-07A325,00000Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-01-07A41,66700RSUForm 4 ↗
Thomas J. RigaCOO and CCO2025-01-07A54,27500RSUForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-01-07A65,00000Derivative, Class A CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-01-07A10,85500RSUForm 4 ↗
Allen MelemedCHIEF MEDICAL OFFICER2025-01-07A275,00000Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-01-07A250,00000Derivative, Class A CommonForm 4 ↗
Allen MelemedCHIEF MEDICAL OFFICER2025-01-07A45,92500RSUForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-01-30D2,800411,470CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-01-30D1,01544,172CommonForm 4 ↗
Mike AndrioleDirector2025-01-30D2,35049,636CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-02-13D2,260510,196CommonForm 4 ↗
Michael AlrutzSVP AND GENERAL COUNSEL2025-02-13D1,60057,226CommonForm 4 ↗
Mike AndrioleDirector2025-02-13D7,370533,282CommonForm 4 ↗
Allen MelemedCHIEF MEDICAL OFFICER2025-02-13D3,065513,799CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-02-13D30051,360CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-04-21D9,360——Derivative, Class A CommonForm 4 ↗
Robert J. MeyerDirector2025-04-21D35,000——Derivative, Class A CommonForm 4 ↗
Pratik S. MultaniDirector2025-04-21D35,000——Derivative, Class A CommonForm 4 ↗
Michael AlrutzSVP AND GENERAL COUNSEL2025-04-21D250,000——Derivative, Class A CommonForm 4 ↗
Michael AlrutzSVP AND GENERAL COUNSEL2025-04-21D176,000——Derivative, Class A CommonForm 4 ↗
Michael AlrutzSVP AND GENERAL COUNSEL2025-04-21D45,750——Derivative, Class A CommonForm 4 ↗
Michael AlrutzSVP AND GENERAL COUNSEL2025-04-21D15,000——Derivative, Class A CommonForm 4 ↗
Mike AndrioleDirector2025-04-21D150,000——Derivative, Class A CommonForm 4 ↗
Mike AndrioleDirector2025-04-21D192,825——Derivative, Class A CommonForm 4 ↗
Mike AndrioleDirector2025-04-21D250,000——Derivative, Class A CommonForm 4 ↗
Lisa L. DeckerDirector2025-04-21D60,000——Derivative, Class A CommonForm 4 ↗
Lisa L. DeckerDirector2025-04-21D100,000——Derivative, Class A CommonForm 4 ↗
Martha J. DemskiDirector2025-04-21D60,000——Derivative, Class A CommonForm 4 ↗
Martha J. DemskiDirector2025-04-21D35,000——Derivative, Class A CommonForm 4 ↗
Martha J. DemskiDirector2025-04-21D21,000——Derivative, Class A CommonForm 4 ↗
Martha J. DemskiDirector2025-04-21D9,000——Derivative, Class A CommonForm 4 ↗
Martha J. DemskiDirector2025-04-21D9,000——Derivative, Class A CommonForm 4 ↗
Martha J. DemskiDirector2025-04-21D72,0559616,070CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-04-21D65,000——Derivative, Class A CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-04-21D18,000——Derivative, Class A CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-04-21D29,900——Derivative, Class A CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-04-21D28,320——Derivative, Class A CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-04-21D10,000——Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-04-21D150,000——Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-04-21D64,275——Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-04-21D90,000——Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-04-21D62,067——Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-04-21D8,098——Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-04-21D13,000——Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-04-21D1,250——Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-04-21D15,000——Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-04-21D181,54191,552,176CommonForm 4 ↗
Allen MelemedCHIEF MEDICAL OFFICER2025-04-21D275,000——Derivative, Class A CommonForm 4 ↗
Allen MelemedCHIEF MEDICAL OFFICER2025-04-21D240,000——Derivative, Class A CommonForm 4 ↗
Allen MelemedCHIEF MEDICAL OFFICER2025-04-21D173,85291,486,435CommonForm 4 ↗
Robert J. MeyerDirector2025-04-21D60,000——Derivative, Class A CommonForm 4 ↗
Robert J. MeyerDirector2025-04-21D35,000——Derivative, Class A CommonForm 4 ↗
Robert J. MeyerDirector2025-04-21D21,000——Derivative, Class A CommonForm 4 ↗
Fred A. MiddletonDirector2025-04-21D50,000——Derivative, Class A CommonForm 4 ↗
Fred A. MiddletonDirector2025-04-21D21,000——Derivative, Class A CommonForm 4 ↗
Fred A. MiddletonDirector2025-04-21D42,000——Derivative, Class A CommonForm 4 ↗
Fred A. MiddletonDirector2025-04-21D531,86194,547,412Common, indirectForm 4 ↗
Fred A. MiddletonDirector2025-04-21D2,776,093923,735,595Common, indirectForm 4 ↗
Fred A. MiddletonDirector2025-04-21D60,0009513,000CommonForm 4 ↗
Fred A. MiddletonDirector2025-04-21D40,0009342,000CommonForm 4 ↗
Pratik S. MultaniDirector2025-04-21D60,000——Derivative, Class A CommonForm 4 ↗
Pratik S. MultaniDirector2025-04-21D50,000——Derivative, Class A CommonForm 4 ↗
Pratik S. MultaniDirector2025-04-21D35,000——Derivative, Class A CommonForm 4 ↗
Thomas J. RigaCOO and CCO2025-04-21D800,000——Derivative, Class A CommonForm 4 ↗
Thomas J. RigaCOO and CCO2025-04-21D60,8289520,079CommonForm 4 ↗
Mike ShermanDirector2025-04-21D60,000——Derivative, Class A CommonForm 4 ↗
Mike ShermanDirector2025-04-21D557,050——Derivative, Class A CommonForm 4 ↗
Mike ShermanDirector2025-04-21D700,000——Derivative, Class A CommonForm 4 ↗
Mike ShermanDirector2025-04-21D632,500——Derivative, Class A CommonForm 4 ↗
Mike ShermanDirector2025-04-21D1,150,000——Derivative, Class A CommonForm 4 ↗
Mike ShermanDirector2025-04-21D233,41391,995,681CommonForm 4 ↗
Mike ShermanDirector2025-04-21D102,9959880,607CommonForm 4 ↗
Vicki VakienerDirector2025-04-21D50,000——Derivative, Class A CommonForm 4 ↗
Vicki VakienerDirector2025-04-21D60,000——Derivative, Class A CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-04-21D1,250——Derivative, Class A CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-04-21D10,000——Derivative, Class A CommonForm 4 ↗
Michael AlrutzSVP AND GENERAL COUNSEL2025-04-21D131,250——Derivative, Class A CommonForm 4 ↗
Michael AlrutzSVP AND GENERAL COUNSEL2025-04-21D170,000——Derivative, Class A CommonForm 4 ↗
Michael AlrutzSVP AND GENERAL COUNSEL2025-04-21D135,000——Derivative, Class A CommonForm 4 ↗
Mike AndrioleDirector2025-04-21D502,500——Derivative, Class A CommonForm 4 ↗
Martha J. DemskiDirector2025-04-21D60,000——Derivative, Class A CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-04-21D24,950——Derivative, Class A CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-04-21D156,20991,335,587CommonForm 4 ↗
Marc D. KozinDirector2025-04-21D100,000——Derivative, Class A CommonForm 4 ↗
Allen MelemedCHIEF MEDICAL OFFICER2025-04-21D168,750——Derivative, Class A CommonForm 4 ↗
Fred A. MiddletonDirector2025-04-21D35,000——Derivative, Class A CommonForm 4 ↗
Fred A. MiddletonDirector2025-04-21D207,52391,774,322CommonForm 4 ↗
Vicki VakienerDirector2025-04-21D60,000——Derivative, Class A CommonForm 4 ↗
Vicki VakienerDirector2025-04-21D60,000——Derivative, Class A CommonForm 4 ↗
Vicki VakienerDirector2025-04-21D35,000——Derivative, Class A CommonForm 4 ↗
Michael AlrutzSVP AND GENERAL COUNSEL2025-04-21D128,550——Derivative, Class A CommonForm 4 ↗
Michael AlrutzSVP AND GENERAL COUNSEL2025-04-21D200,000——Derivative, Class A CommonForm 4 ↗
Martha J. DemskiDirector2025-04-21D21,000——Derivative, Class A CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-04-21D64,500——Derivative, Class A CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-04-21D30,000——Derivative, Class A CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-04-21D1,500——Derivative, Class A CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-04-21D10,150——Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-04-21D17,000——Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-04-21D48,438——Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-04-21D1,500——Derivative, Class A CommonForm 4 ↗
Robert J. MeyerDirector2025-04-21D42,000——Derivative, Class A CommonForm 4 ↗
Thomas J. RigaCOO and CCO2025-04-21D325,000——Derivative, Class A CommonForm 4 ↗
Mike ShermanDirector2025-04-21D875,000——Derivative, Class A CommonForm 4 ↗
Mike ShermanDirector2025-04-21D87,0009743,850CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-04-21D1,500——Derivative, Class A CommonForm 4 ↗
Mike AndrioleDirector2025-04-21D900,000——Derivative, Class A CommonForm 4 ↗
Mike AndrioleDirector2025-04-21D300,000——Derivative, Class A CommonForm 4 ↗
Mike AndrioleDirector2025-04-21D450,000——Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-04-21D250,000——Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-04-21D95,000——Derivative, Class A CommonForm 4 ↗
Michelle LaSpalutoCHIEF FINANCIAL OFFICER2025-04-21D18,700——Derivative, Class A CommonForm 4 ↗
Robert J. MeyerDirector2025-04-21D35,1509300,533CommonForm 4 ↗
Pratik S. MultaniDirector2025-04-21D60,000——Derivative, Class A CommonForm 4 ↗
Michael AlrutzSVP AND GENERAL COUNSEL2025-04-21D165,000——Derivative, Class A CommonForm 4 ↗
Michael AlrutzSVP AND GENERAL COUNSEL2025-04-21D216,68991,852,691CommonForm 4 ↗
Mike AndrioleDirector2025-04-21D630,82895,393,579CommonForm 4 ↗
David JakemanVP OF FINANCE AND ACCOUNTING2025-04-21D7,200——Derivative, Class A CommonForm 4 ↗
Mike AndrioleDirector2025-04-21D192,500——Derivative, Class A CommonForm 4 ↗
Robert J. MeyerDirector2025-04-21D21,000——Derivative, Class A CommonForm 4 ↗
Pratik S. MultaniDirector2025-04-21D60,000——Derivative, Class A CommonForm 4 ↗
Allen MelemedCHIEF MEDICAL OFFICER2025-04-21D154,260——Derivative, Class A CommonForm 4 ↗
Allen MelemedCHIEF MEDICAL OFFICER2025-04-21D190,000——Derivative, Class A CommonForm 4 ↗
Allen MelemedCHIEF MEDICAL OFFICER2025-04-21D400,000——Derivative, Class A CommonForm 4 ↗
Robert J. MeyerDirector2025-04-21D60,000——Derivative, Class A CommonForm 4 ↗
Fred A. MiddletonDirector2025-04-21D60,000——Derivative, Class A CommonForm 4 ↗
Fred A. MiddletonDirector2025-04-21D60,000——Derivative, Class A CommonForm 4 ↗
Fred A. MiddletonDirector2025-04-21D35,000——Derivative, Class A CommonForm 4 ↗
Fred A. MiddletonDirector2025-04-21D21,000——Derivative, Class A CommonForm 4 ↗
Marc D. KozinDirector2025-04-21D60,000——Derivative, Class A CommonForm 4 ↗
Martha J. DemskiDirector2025-04-21D50,000——Derivative, Class A CommonForm 4 ↗
Martha J. DemskiDirector2025-04-21D21,000——Derivative, Class A CommonForm 4 ↗
Robert J. MeyerDirector2025-04-21D50,000——Derivative, Class A CommonForm 4 ↗
Michael AlrutzSVP AND GENERAL COUNSEL2025-04-21D178,000——Derivative, Class A CommonForm 4 ↗
Martha J. DemskiDirector2025-04-21D35,000——Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2023

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
On AugOptions/SARs———150,000—$25,000
03b

Vehicle mix — grant-date fair value by award type

Grant-level vehicle detail not disclosed.

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2023

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Mike AndrioleRSU25,000—$24,063
Allen MelemedOption118,9091.97—
Mike ShermanRSU92,950—89,464
Mike AndrioleOption4,0112.08—
Michael AlrutzOption99,0911.97—
Mike AndrioleRSU32,175—30,968
Allen MelemedRSU25,740—24,775
Michael AlrutzOption46,0429.28—
Michael AlrutzRSU21,450—20,646
Mike AndrioleOption67,7089.28—
Mike AndrioleOption156,2505.62—
Mike AndrioleOption148,6361.97—
Mike AndrioleOption150,0001.19—
Allen MelemedOption50,0003.11—
Allen MelemedOption51,4599.28—
Allen MelemedOption125,0005.62—
Michael AlrutzOption3,4382.08—
Michael AlrutzOption104,1675.62—
Mike ShermanOption13,1792.08—
Mike ShermanOption189,5849.28—
Mike ShermanOption455,7305.62—
Mike ShermanOption429,3931.97—
05

Incentive-plan design — the Compensation Discussion & Analysis

The executive compensation program is structured to provide a competitive level of base cash compensation, with the opportunity to earn meaningfully more only upon successful performance. This structure motivates executives to achieve results for the business and value for stockholders over the long-term by tying bonuses to defined business objectives and equity awards to stock price appreciation over a multi-year period.

CEO STI target (% of salary)55%
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20242024-06-2037,473,1117,681,297174,81682.99%Passed
20232023-06-0936,914,77610,390,7312,538,52778.03%Passed
20222022-06-2332,981,13020,478,97574,91361.69%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20242024-06-2082.99%a
20232023-06-0978.03%b
20222022-06-2361.69%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2023

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Martha J. DemskiIndependent · Lead Independent Director · Audit$85,000$0$59,522—$0$144,522
Patrick MachadoIndependent · Audit · Compensation (Chair) · Not standing for re-election65,000059,522—0124,522
Fred A. MiddletonIndependent · Audit (Chair)60,000059,522—0119,522
Robert J. MeyerIndependent · Compensation · Nominating and Governance (Chair)57,500059,522—0117,022
Vicki VakienerIndependent · Compensation47,500059,522—0107,022
Pratik S. MultaniIndependent · Nominating and Governance45,000059,522—0104,522
Catherine L. GillissIndependent · Nominating and Governance · Not standing for re-election · Departed during FY45,000059,522—0104,522
Lisa L. DeckerIndependent · Newly elected0067,778—067,778
Marc D. KozinIndependent · Newly elected000—00
Mike AndrioleEmployee director000—00
Mike ShermanIndependent · Board Chair————0—
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2023
Cash retainers and fees$405,000
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$405,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2023

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

ALXO ALX OncologyARCT Arcturus TherapeuticsCRIS CurisARDX ArdelyxBTAI BioXcel TherapeuticsCBAY CymaBay TherapeuticsGTHX G1 TherapeuticsGRTS Gritstone bioMEIP MEI PharmaMCRB Seres TherapeuticsTRVN TrevenaVBIV VBI VaccinesALVR AllovirYMAB Y-mAbs Therapeutics Jounce TherapeuticsCTMX CytomX TherapeuticsDTIL Precision BioSciences
10a

Peer reciprocity

Of the companies Chimerix names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

ALX Oncology (ALXO)— Arcturus Therapeutics (ARCT)171 Curis (CRIS)— Ardelyx (ARDX)172 BioXcel Therapeutics (BTAI) CymaBay Therapeutics (CBAY)— G1 Therapeutics (GTHX)173 Gritstone bio (GRTS) MEI Pharma (MEIP)— Seres Therapeutics (MCRB)174 Trevena (TRVN) VBI Vaccines (VBIV) Allovir (ALVR)— Y-mAbs Therapeutics (YMAB)175 CytomX Therapeutics (CTMX)— Precision BioSciences (DTIL)176

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Chimerix.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Ardelyx2025Michael Raab$797,000$2,953,724$3,413,948$627,638$7,796,171
2CytomX Therapeutics2025Sean McCarthy675,2901,150,4632,158,170749,5724,738,495
3Y-mAbs Therapeutics2024Michael Rossi705,6001,170,7322,288,662392,5964,557,590
4G1 Therapeutics2023John Bailey794,9761,392,022666,209387,5513,250,658
5ALX Oncology2025Jason Lettmann724,50001,447,488298,8562,470,844
6Precision BioSciences2025Michael Amoroso650,8751,025,086002,189,467
7Seres Therapeutics2025Eric Shaff408,33301,338,87001,775,549
8Arcturus Therapeutics2025Joseph Payne750,0000941,00001,691,000
9Curis2025James Dentzer672,2000736,169218,1961,659,756
10Chimerix2023Mike Andriole528,47393,135399,282280,5001,312,421
—BioXcel Therapeutics——————not in coverage universe
—CymaBay Therapeutics——————not in coverage universe
—Gritstone bio——————not in coverage universe
—MEI Pharma——————not in coverage universe
—Trevena——————not in coverage universe
—VBI Vaccines——————not in coverage universe
—Allovir——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Chimerix85%Option 86 · RSU 14not disclosedAon
Allovirnot disclosedOption 100not disclosedAon plc
ALX Oncologynot disclosednot disclosednot disclosedCompensia
Arcturus Therapeuticsnot disclosedOptions 100not disclosednot disclosed
Ardelyx105%Options 50 · RSU 50not disclosedPearl Meyer
BioXcel Therapeuticsnot disclosednot disclosednot disclosedRadford, a part of Aon plc
Curisnot disclosedOption 100not disclosedWillis Towers Watson
CymaBay Therapeuticsnot disclosednot disclosednot disclosednot disclosed
CytomX Therapeuticsnot disclosednot disclosednot disclosedAon
G1 Therapeuticsnot disclosednot disclosednot disclosedRadford, Aon’s Human Capital Solutions Practice
Gritstone bionot disclosednot disclosednot disclosednot disclosed
MEI Pharmanot disclosednot disclosednot disclosedF. W. Cook
Precision BioSciences115%RSU 100not disclosedAon
Seres Therapeuticsnot disclosedOptions 100not disclosedAlpine Rewards, LLC
Trevenanot disclosednot disclosednot disclosednot disclosed
VBI Vaccinesnot disclosednot disclosednot disclosednot disclosed
Y-mAbs Therapeutics85.6%not disclosedNoAon

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Chimerix in fiscal 2023?
As disclosed, Mike Sherman (Former President and Chief Executive Officer) was the highest-paid executive at Chimerix in fiscal 2023, with total compensation of $1,517,854.
How does Chimerix's chief executive pay compare to its disclosed peer group?
As disclosed, Mike Andriole's total compensation ranked at the 1st percentile of Chimerix's disclosed peer group.
How did shareholders vote on Chimerix's executive compensation?
As disclosed, 82.99% of shareholders supported Chimerix's executive compensation in the latest say-on-pay vote.
How much does Chimerix spend in total on board compensation for fiscal 2023?
As disclosed, Chimerix reported total board compensation of $405,000 for fiscal 2023.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Mike ShermanDEF 14A2024-04-260001117480-24-000010Section “Executive Compensation”. As printed: 1,517,854. Filing ↗
2Section 01, Mike AndrioleDEF 14A2024-04-260001117480-24-000010Section “Executive Compensation”. As printed: 1,312,421. Filing ↗
3Section 01, Allen MelemedDEF 14A2024-04-260001117480-24-000010Section “Executive Compensation”. As printed: 931,794. Filing ↗
4Section 01, Michael AlrutzDEF 14A2024-04-260001117480-24-000010Section “Executive Compensation”. As printed: 793,854. Filing ↗machine: r4 · c24 · span 474795–474802
5Section 03, On Aug Options/SARsDEF 14A2024-04-260001117480-24-000010Section “EXECUTIVE AND DIRECTOR COMPENSATION EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t18 · r6 · c0 · span 511586–511592
6Section 08, Martha J. DemskiDEF 14A2024-04-260001117480-24-000010Section “Director Compensation”. As printed: 144,522. Filing ↗machine: span 677143–677393
7Section 08, Patrick MachadoDEF 14A2024-04-260001117480-24-000010Section “Director Compensation”. As printed: 124,522. Filing ↗machine: span 679731–679981
8Section 08, Fred A. MiddletonDEF 14A2024-04-260001117480-24-000010Section “Director Compensation”. As printed: 119,522. Filing ↗machine: span 682117–682367
9Section 08, Robert J. MeyerDEF 14A2024-04-260001117480-24-000010Section “Director Compensation”. As printed: 117,022. Filing ↗machine: span 680926–681176
10Section 08, Vicki VakienerDEF 14A2024-04-260001117480-24-000010Section “Director Compensation”. As printed: 107,022. Filing ↗machine: span 684642–684892
11Section 08, Pratik S. MultaniDEF 14A2024-04-260001117480-24-000010Section “Director Compensation”. As printed: 104,522. Filing ↗machine: span 683314–683564
12Section 08, Catherine L. GillissDEF 14A2024-04-260001117480-24-000010Section “Director Compensation”. As printed: 104,522. Filing ↗machine: span 678542–678792
13Section 08, Lisa L. DeckerDEF 14A2024-04-260001117480-24-000010Section “Director Compensation”. As printed: 67,778. Filing ↗machine: span 675632–675881
14Section 08, Marc D. KozinDEF 14A2024-04-260001117480-24-000010Section “Director Compensation”. As printed: 0. Filing ↗
15Section 08, Mike AndrioleDEF 14A2024-04-260001117480-24-000010Section “Director Compensation”. As printed: 0. Filing ↗
16Section 08, Mike ShermanDEF 14A2024-04-260001117480-24-000010Section “Director Compensation”. As printed: —. Filing ↗
17Section 02, Mike Andriole 2025-01-07Form 42025-01-100001415889-25-001219Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Mike Andriole 2025-01-07Form 42025-01-100001415889-25-001219Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Michael Alrutz 2025-01-07Form 42025-01-100001415889-25-001220Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Michael Alrutz 2025-01-07Form 42025-01-100001415889-25-001220Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Thomas J. Riga 2025-01-07Form 42025-01-100001415889-25-001221Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Michelle LaSpaluto 2025-01-07Form 42025-01-100001415889-25-001224Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Thomas J. Riga 2025-01-07Form 42025-01-100001415889-25-001221Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, David Jakeman 2025-01-07Form 42025-01-100001415889-25-001222Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, David Jakeman 2025-01-07Form 42025-01-100001415889-25-001222Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Allen Melemed 2025-01-07Form 42025-01-100001415889-25-001223Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Michelle LaSpaluto 2025-01-07Form 42025-01-100001415889-25-001224Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Allen Melemed 2025-01-07Form 42025-01-100001415889-25-001223Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, David Jakeman 2025-01-30Form 42025-01-310001415889-25-002500Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Michelle LaSpaluto 2025-01-30Form 42025-01-310001415889-25-002498Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Mike Andriole 2025-01-30Form 42025-01-310001415889-25-002496Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Michelle LaSpaluto 2025-02-13Form 42025-02-140001415889-25-004212Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Michael Alrutz 2025-02-13Form 42025-02-140001415889-25-004216Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Mike Andriole 2025-02-13Form 42025-02-140001415889-25-004218Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Allen Melemed 2025-02-13Form 42025-02-140001415889-25-004219Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, David Jakeman 2025-02-13Form 42025-02-140001415889-25-004213Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, David Jakeman 2025-04-21Form 42025-04-210001415889-25-011070Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Robert J. Meyer 2025-04-21Form 42025-04-210001415889-25-011075Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Pratik S. Multani 2025-04-21Form 42025-04-210001415889-25-011078Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Michael Alrutz 2025-04-21Form 42025-04-210001415889-25-011064Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Michael Alrutz 2025-04-21Form 42025-04-210001415889-25-011064Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Michael Alrutz 2025-04-21Form 42025-04-210001415889-25-011064Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Michael Alrutz 2025-04-21Form 42025-04-210001415889-25-011064Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Mike Andriole 2025-04-21Form 42025-04-210001415889-25-011066Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Mike Andriole 2025-04-21Form 42025-04-210001415889-25-011066Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Mike Andriole 2025-04-21Form 42025-04-210001415889-25-011066Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Lisa L. Decker 2025-04-21Form 42025-04-210001415889-25-011068Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Lisa L. Decker 2025-04-21Form 42025-04-210001415889-25-011068Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Martha J. Demski 2025-04-21Form 42025-04-210001415889-25-011069Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Martha J. Demski 2025-04-21Form 42025-04-210001415889-25-011069Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Martha J. Demski 2025-04-21Form 42025-04-210001415889-25-011069Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Martha J. Demski 2025-04-21Form 42025-04-210001415889-25-011069Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Martha J. Demski 2025-04-21Form 42025-04-210001415889-25-011069Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Martha J. Demski 2025-04-21Form 42025-04-210001415889-25-011069Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, David Jakeman 2025-04-21Form 42025-04-210001415889-25-011070Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, David Jakeman 2025-04-21Form 42025-04-210001415889-25-011070Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, David Jakeman 2025-04-21Form 42025-04-210001415889-25-011070Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, David Jakeman 2025-04-21Form 42025-04-210001415889-25-011070Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, David Jakeman 2025-04-21Form 42025-04-210001415889-25-011070Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Michelle LaSpaluto 2025-04-21Form 42025-04-210001415889-25-011073Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Michelle LaSpaluto 2025-04-21Form 42025-04-210001415889-25-011073Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Michelle LaSpaluto 2025-04-21Form 42025-04-210001415889-25-011073Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Michelle LaSpaluto 2025-04-21Form 42025-04-210001415889-25-011073Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Michelle LaSpaluto 2025-04-21Form 42025-04-210001415889-25-011073Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Michelle LaSpaluto 2025-04-21Form 42025-04-210001415889-25-011073Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Michelle LaSpaluto 2025-04-21Form 42025-04-210001415889-25-011073Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Michelle LaSpaluto 2025-04-21Form 42025-04-210001415889-25-011073Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Michelle LaSpaluto 2025-04-21Form 42025-04-210001415889-25-011073Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Allen Melemed 2025-04-21Form 42025-04-210001415889-25-011074Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Allen Melemed 2025-04-21Form 42025-04-210001415889-25-011074Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Allen Melemed 2025-04-21Form 42025-04-210001415889-25-011074Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Robert J. Meyer 2025-04-21Form 42025-04-210001415889-25-011075Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Robert J. Meyer 2025-04-21Form 42025-04-210001415889-25-011075Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Robert J. Meyer 2025-04-21Form 42025-04-210001415889-25-011075Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Fred A. Middleton 2025-04-21Form 42025-04-210001415889-25-011076Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Fred A. Middleton 2025-04-21Form 42025-04-210001415889-25-011076Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Fred A. Middleton 2025-04-21Form 42025-04-210001415889-25-011076Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Fred A. Middleton 2025-04-21Form 42025-04-210001415889-25-011076Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Fred A. Middleton 2025-04-21Form 42025-04-210001415889-25-011076Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Fred A. Middleton 2025-04-21Form 42025-04-210001415889-25-011076Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Fred A. Middleton 2025-04-21Form 42025-04-210001415889-25-011076Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Pratik S. Multani 2025-04-21Form 42025-04-210001415889-25-011078Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Pratik S. Multani 2025-04-21Form 42025-04-210001415889-25-011078Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Pratik S. Multani 2025-04-21Form 42025-04-210001415889-25-011078Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Thomas J. Riga 2025-04-21Form 42025-04-210001415889-25-011079Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Thomas J. Riga 2025-04-21Form 42025-04-210001415889-25-011079Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Mike Sherman 2025-04-21Form 42025-04-210001415889-25-011081Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Mike Sherman 2025-04-21Form 42025-04-210001415889-25-011081Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Mike Sherman 2025-04-21Form 42025-04-210001415889-25-011081Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Mike Sherman 2025-04-21Form 42025-04-210001415889-25-011081Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Mike Sherman 2025-04-21Form 42025-04-210001415889-25-011081Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Mike Sherman 2025-04-21Form 42025-04-210001415889-25-011081Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Mike Sherman 2025-04-21Form 42025-04-210001415889-25-011081Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Vicki Vakiener 2025-04-21Form 42025-04-210001415889-25-011082Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Vicki Vakiener 2025-04-21Form 42025-04-210001415889-25-011082Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, David Jakeman 2025-04-21Form 42025-04-210001415889-25-011070Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, David Jakeman 2025-04-21Form 42025-04-210001415889-25-011070Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Michael Alrutz 2025-04-21Form 42025-04-210001415889-25-011064Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Michael Alrutz 2025-04-21Form 42025-04-210001415889-25-011064Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Michael Alrutz 2025-04-21Form 42025-04-210001415889-25-011064Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Mike Andriole 2025-04-21Form 42025-04-210001415889-25-011066Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Martha J. Demski 2025-04-21Form 42025-04-210001415889-25-011069Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, David Jakeman 2025-04-21Form 42025-04-210001415889-25-011070Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, David Jakeman 2025-04-21Form 42025-04-210001415889-25-011070Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Marc D. Kozin 2025-04-21Form 42025-04-210001415889-25-011071Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Allen Melemed 2025-04-21Form 42025-04-210001415889-25-011074Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Fred A. Middleton 2025-04-21Form 42025-04-210001415889-25-011076Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Fred A. Middleton 2025-04-21Form 42025-04-210001415889-25-011076Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Vicki Vakiener 2025-04-21Form 42025-04-210001415889-25-011082Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Vicki Vakiener 2025-04-21Form 42025-04-210001415889-25-011082Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Vicki Vakiener 2025-04-21Form 42025-04-210001415889-25-011082Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Michael Alrutz 2025-04-21Form 42025-04-210001415889-25-011064Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Michael Alrutz 2025-04-21Form 42025-04-210001415889-25-011064Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Martha J. Demski 2025-04-21Form 42025-04-210001415889-25-011069Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, David Jakeman 2025-04-21Form 42025-04-210001415889-25-011070Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, David Jakeman 2025-04-21Form 42025-04-210001415889-25-011070Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, David Jakeman 2025-04-21Form 42025-04-210001415889-25-011070Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, David Jakeman 2025-04-21Form 42025-04-210001415889-25-011070Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Michelle LaSpaluto 2025-04-21Form 42025-04-210001415889-25-011073Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Michelle LaSpaluto 2025-04-21Form 42025-04-210001415889-25-011073Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Michelle LaSpaluto 2025-04-21Form 42025-04-210001415889-25-011073Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Robert J. Meyer 2025-04-21Form 42025-04-210001415889-25-011075Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Thomas J. Riga 2025-04-21Form 42025-04-210001415889-25-011079Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Mike Sherman 2025-04-21Form 42025-04-210001415889-25-011081Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Mike Sherman 2025-04-21Form 42025-04-210001415889-25-011081Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, David Jakeman 2025-04-21Form 42025-04-210001415889-25-011070Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Mike Andriole 2025-04-21Form 42025-04-210001415889-25-011066Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Mike Andriole 2025-04-21Form 42025-04-210001415889-25-011066Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Mike Andriole 2025-04-21Form 42025-04-210001415889-25-011066Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Michelle LaSpaluto 2025-04-21Form 42025-04-210001415889-25-011073Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Michelle LaSpaluto 2025-04-21Form 42025-04-210001415889-25-011073Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Michelle LaSpaluto 2025-04-21Form 42025-04-210001415889-25-011073Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, Robert J. Meyer 2025-04-21Form 42025-04-210001415889-25-011075Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, Pratik S. Multani 2025-04-21Form 42025-04-210001415889-25-011078Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, Michael Alrutz 2025-04-21Form 42025-04-210001415889-25-011064Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Michael Alrutz 2025-04-21Form 42025-04-210001415889-25-011064Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Mike Andriole 2025-04-21Form 42025-04-210001415889-25-011066Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, David Jakeman 2025-04-21Form 42025-04-210001415889-25-011070Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Mike Andriole 2025-04-21Form 42025-04-210001415889-25-011066Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Robert J. Meyer 2025-04-21Form 42025-04-210001415889-25-011075Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Pratik S. Multani 2025-04-21Form 42025-04-210001415889-25-011078Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Allen Melemed 2025-04-21Form 42025-04-210001415889-25-011074Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Allen Melemed 2025-04-21Form 42025-04-210001415889-25-011074Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Allen Melemed 2025-04-21Form 42025-04-210001415889-25-011074Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Robert J. Meyer 2025-04-21Form 42025-04-210001415889-25-011075Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Fred A. Middleton 2025-04-21Form 42025-04-210001415889-25-011076Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Fred A. Middleton 2025-04-21Form 42025-04-210001415889-25-011076Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Fred A. Middleton 2025-04-21Form 42025-04-210001415889-25-011076Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Fred A. Middleton 2025-04-21Form 42025-04-210001415889-25-011076Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Marc D. Kozin 2025-04-21Form 42025-04-210001415889-25-011071Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, Martha J. Demski 2025-04-21Form 42025-04-210001415889-25-011069Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Martha J. Demski 2025-04-21Form 42025-04-210001415889-25-011069Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Robert J. Meyer 2025-04-21Form 42025-04-210001415889-25-011075Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Michael Alrutz 2025-04-21Form 42025-04-210001415889-25-011064Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Martha J. Demski 2025-04-21Form 42025-04-210001415889-25-011069Insider equity transaction reported since the proxy statement. Filing ↗
156Section 06, 2024 voteForm 8-K2024-06-210001104659-24-073907Item 5.07 · say-on-pay result. As reported: 82.99% (votes for as printed: 37,473,111). Filing ↗
157Section 06, 2023 voteForm 8-K2023-06-120001104659-23-070155Item 5.07 · say-on-pay result. As reported: 78.03% (votes for as printed: 36,914,776). Filing ↗
158Section 06, 2022 voteForm 8-K2022-06-280001117480-22-000027Item 5.07 · say-on-pay result. As reported: 61.69% (votes for as printed: 32,981,130). Filing ↗
159Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
160Section 09b board cost (computed)Computed——Cash 405,000 + equity 0 + all other 0 = 405,000, summed across the director compensation table rows.machine: formula: Σ = 405,000
161Ardelyx, Section 10b CEO totalDEF 14A2026-04-290001140361-26-017800CEO total compensation as printed in Ardelyx's own proxy. As printed: 7,796,171. Filing ↗machine: r2 · c25 · span 677112–677121
162CytomX Therapeutics, Section 10b CEO totalDEF 14A2026-04-300001140361-26-018237CEO total compensation as printed in CytomX Therapeutics's own proxy. As printed: 4,738,495. Filing ↗machine: r2 · c24 · span 739353–739362
163Y-mAbs Therapeutics, Section 10b CEO totalDEF 14A2025-05-300001558370-25-008299CEO total compensation as printed in Y-mAbs Therapeutics's own proxy. As printed: 4,557,590. Filing ↗machine: r5 · c23 · span 597595–597604
164G1 Therapeutics, Section 10b CEO totalDEF 14A2024-04-250001193125-24-113902CEO total compensation as printed in G1 Therapeutics's own proxy. As printed: 3,250,658. Filing ↗machine: r3 · c31 · span 348805–348814
165ALX Oncology, Section 10b CEO totalDEF 14A2026-04-200001193125-26-163936CEO total compensation as printed in ALX Oncology's own proxy. As printed: 2,470,844. Filing ↗machine: r2 · c29 · span 706901–706910
166Precision BioSciences, Section 10b CEO totalDEF 14A2026-04-080001140361-26-013757CEO total compensation as printed in Precision BioSciences's own proxy. As printed: 2,189,467. Filing ↗machine: r2 · c19 · span 829996–830005
167Seres Therapeutics, Section 10b CEO totalDEF 14A2026-04-270001193125-26-182036CEO total compensation as printed in Seres Therapeutics's own proxy. As printed: 1,775,549. Filing ↗machine: r2 · c29 · span 928055–928064
168Arcturus Therapeutics, Section 10b CEO totalDEF 14A2026-04-240001193805-26-000507CEO total compensation as printed in Arcturus Therapeutics's own proxy. As printed: 1,691,000. Filing ↗machine: t116 · r1 · c27 · span 296910–296919
169Curis, Section 10b CEO totalDEF 14A2026-04-210001108205-26-000053CEO total compensation as printed in Curis's own proxy. As printed: 1,659,756. Filing ↗
170Chimerix (subject), Section 10b CEO totalDEF 14A2024-04-260001117480-24-000010CEO total compensation as printed in Chimerix's own proxy. As printed: 1,312,421. Filing ↗
171Section 10a, Arcturus Therapeutics reciprocityDEF 14A—0001193805-26-000507Arcturus Therapeutics's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗
172Section 10a, Ardelyx reciprocityDEF 14A—0001140361-26-017800Ardelyx's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗
173Section 10a, G1 Therapeutics reciprocityDEF 14A—0001193125-24-113902G1 Therapeutics's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗
174Section 10a, Seres Therapeutics reciprocityDEF 14A—0001193125-26-182036Seres Therapeutics's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗
175Section 10a, Y-mAbs Therapeutics reciprocityDEF 14A—0001558370-25-008299Y-mAbs Therapeutics's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗
176Section 10a, Precision BioSciences reciprocityDEF 14A—0001140361-26-013757Precision BioSciences's most recent proxy was read; its disclosed peer group does not include Chimerix. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.